natgillin/translations-raw huggingface dataset:
In clinical studies with rotigotine, syncope has been observed at a rate that was similar to that observed in patients treated with placebo.
U kliničkim ispitivanjima s rotigotinom primijećena je sinkopa sa stopom sličnom onoj primjećenoj u bolesnika koji su primali placebo.
In clinical studies with tocilizumab, rapid decreases in CRP, erythrocyte sedimentation rate (ESR) and serum amyloid A (SAA) were observed.
U kliničkim ispitivanjima tocilizumaba primijećena su nagla smanjenja vrijednosti C-reaktivnog proteina (CRP), brzine sedimentacije eritrocita (SE) i serumskog amiloida A (SAA).
In clinical studies with topotecan in combination with cisplatin for the treatment of cervical cancer, therapy was only initiated in patients with serum creatinine less than or equal to 132 μmol/l.
U kliničkim ispitivanjima kombinacije topotekana i cisplatine u liječenju karcinoma vrata maternice, liječenje je započeto samo u bolesnica s vrijednošću kreatinina u serumu manjom ili jednakom 132 μmol/l.
In clinical studies with Ultibro Breezhaler, paradoxical bronchospasm was not observed.
U kliničkim ispitivanjima sa Ultibro Breezhalerom nije bio uočen paradoksalni bronhospazam.
In clinical studies with Ulunar Breezhaler, paradoxical bronchospasm was not observed.
U kliničkim ispitivanjima sa Ulunar Breezhalerom nije bio uočen paradoksalni bronhospazam.
In clinical studies with Xoterna Breezhaler, paradoxical bronchospasm was not observed.
U kliničkim ispitivanjima sa Xoterna Breezhalerom nije bio uočen paradoksalni bronhospazam.
In clinical studies – Genotype 1
U kliničkim ispitivanjima – genotip 1
In clinical studies – Genotype 2, 3, 4, 5 and 6
U kliničkim ispitivanjima – genotip 2, 3, 4, 5 i 6
In clinical studies, 0.1% of patients (7 out of 4846 patients with primary hyperlipidaemia and mixed dyslipidaemia and 0 out of 80 patients with homozygous familial hypercholesterolaemia) treated with at least one dose of Repatha tested positive for binding antibody development (4 of these patients had transient antibodies).
U kliničkim ispitivanjima, 0,1% bolesnika (7 od 4846 bolesnika s primarnom hiperlipidemijom i miješanom dislipidemijom i 0 od 80 bolesnika s homozigotnom obiteljskom hiperkolesterolemijom) liječenih s najmanje jednom dozom lijeka Repatha, bilo je pozitivno na razvoj veznih protutijela (od tih bolesnika 4 su imala prolazna protutijela).
In clinical studies, 1,865 adult individuals received single or multiple doses of caspofungin:
U kliničkim je ispitivanjima 1865 odraslih ispitanika primilo pojedinačnu ili višekratnu dozu kaspofungina: 564 febrilnih bolesnika s neutropenijom (ispitivanje empirijskog liječenja),
In clinical studies, 2,011 subjects received Cubicin.
U kliničkim je ispitivanjima Cubicin primalo 2011 ispitanika.
In clinical studies, 60.2% of women aged 16 through 26 years who received Gardasil 9 used hormonal contraceptives during the vaccination period of the clinical studies.
U kliničkim ispitivanjima, 60,2% žena u dobi od 16 do 26 godina koje su primile Gardasil 9 uzimalo je hormonske kontraceptive tijekom razdoblja cijepljenja u kliničkim ispitivanjima.
In clinical studies, 88.9% (8/9) of patients with late first relapse as defined in the individual studies achieved CR/CRh* within the first 2 treatment cycles with 62.5% (6/9) achieving MRD response and 37.5 % (3/9) undergoing allogeneic HSCT after treatment with BLINCYTO.
U kliničkim ispitivanjima, 88,9% (8/9) bolesnika s kasnim prvim recidivom, kako je definirano u pojedinim ispitivanjima, postiglo je CR/CRh* unutar prva 2 ciklusa liječenja, s 62,5% (6/9) bolesnika koji su postigli MRB odgovor, i 37,5% (3/9) bolesnika u kojih je provedena alogena HSCT nakon liječenja lijekom BLINCYTO.
In clinical studies, a post-mortem examination of the injection site, performed 8 weeks after the administration of a single dose of the vaccine, revealed a mild to moderate granulomatous inflammation of the muscular fibres at the injection site.
Prilikom kliničke studije, patoanatomski obdukcijski nalaz mjesta aplikacije izvršene osam tjedana nakon aplikacije jedne doze vakcine pokazao je blagu do umjerenu granulomatoznu upalu mišićnog tkiva.
In clinical studies, a small number of patients fainted.
U kliničkim je ispitivanjima mali broj bolesnika izgubio svijest.
In clinical studies, Activyl was co-administered with deltamethrin collars impregnated with up to 4% deltamethrin without evidence of associated adverse reactions.
Kod kliničkih ispitivanja, Activyl se davao zajedno sa ogrlicama sa deltametrinom impregniranih sa 4% deltametrinom bez zabilježenih nuspojava.
In clinical studies, Activyl was co-administered with deltamethrin collars impregnated with up to 4% deltamethrin without evidence of associated adverse reactions.
U kliničkim ispitivanjima, Activyl se davao s deltametrin ogrlicama impregniranim sa 4% deltametrina bez vidljivih znakova nuspojava.
In clinical studies, adverse reactions were more frequently reported in patients aged from 6 to less than 18 years old than in adults.
U kliničkim ispitivanjima nuspojave su bile češće prijavljivane u bolesnika u dobi od 6 do manje od 18 godina, nego u odraslih.
In clinical studies, after over 3 years (40 months) of treatment arterial and venous occlusive adverse events (clots or blockages in the arteries or veins) occurred in 23% of patients, with serious adverse events occurring in 18% of patients.
Tijekom kliničkih studija, nakon više od tri godine (40 mjeseci) liječenja nuspojave u obliku okluzije arterija i vena (ugrušaka ili začepljenja arterija ili vena) pojavile su se u 23 % bolesnika, pri čemu su ozbiljne nuspojave zabilježene kod 18 % bolesnika.
In clinical studies, alogliptin had no clinically relevant effect on the pharmacokinetics of caffeine, (R)-warfarin, pioglitazone, glyburide, tolbutamide, (S)-warfarin, dextromethorphan, atorvastatin, midazolam, an oral contraceptive (norethindrone and ethinyl oestradiol), digoxin, fexofenadine, metformin, or cimetidine, thus providing in vivo evidence of a low propensity to cause interaction with substrates of CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glycoprotein, and OCT2.
U kliničkim ispitivanjima alogliptin nije imao klinički značajan učinak na farmakokinetiku kofeina, (R)-varfarina, pioglitazona, gliburida, tolbutamida, (S)-varfarina, dekstrometorfana, atorvastatina, midazolama, oralnog kontraceptiva (noretindron i etinil estradiol), digoksina, feksofenadina, metformina ili cimetidina, potvrđujući i in vivo niski potencijal uzrokovanja interakcija sa supstratima za CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glikoprotein i OCT2.
In clinical studies, alogliptin had no clinically relevant effect on the pharmacokinetics of caffeine, (R)-warfarin, pioglitazone, glyburide, tolbutamide, (S)-warfarin, dextromethorphan, atorvastatin, midazolam, an oral contraceptive (norethindrone and ethinyl oestradiol), digoxin, fexofenadine, metformin, or cimetidine, thus providing in vivo evidence of a low propensity to cause interaction with substrates of CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glycoprotein, and OCT2.
U kliničkim ispitivanjima alogliptin nije imao klinički značajan učinak na farmakokinetiku kofeina, (R)-varfarina, pioglitazona, gliburida, tolbutamida, (S)-varfarina, dekstrometorfana, atorvastatina, midazolama, oralnog kontraceptiva (noretindron i etinil estradiol), digoksina, feksofenadina, metformina ili cimetidina, potvrđujući i in vivo niski potencijal uzrokovanja interakcije sa supstratima za CYP1A2, CYP3A4, CYP2D6, CYP2C9, p-glikoproteinom i OCT2.
In clinical studies, antibodies that cross- react with human insulin and insulin glargine were observed with the same frequency in both NPH- insulin and insulin glargine treatment groups.
U kliničkim je ispitivanjima učestalost križnih reakcija protutijela s ljudskim inzulinom i inzulinom glarginom bila podjednaka u skupinama liječenima NPH inzulinom i onima liječenima inzulinom glarginom.
In clinical studies, approximately 78 patients were evaluated with elotuzumab at 20 mg/kg without apparent toxic effects.
U kliničkim ispitivanjima ocjenjivano je približno 78 bolesnika koji su primali dozu elotuzumaba od 20 mg/kg, bez primjetnih toksičnih učinaka.
In clinical studies, apremilast has been administered concomitantly with topical therapy (including corticosteroids, coal tar shampoo and saliycyilic acid scalp preparations) and UVB phototherapy.
U kliničkim ispitivanjima apremilast se primjenjivao istodobno s topikalnom terapijom (uključujući kortikosteroide, šampone na bazi katrana kamenog ugljena te pripravke za vlasište sa salicilnom kiselinom) i terapijom ultraljubičastim B zrakama (UVB).
In clinical studies, cancers were observed in patients receiving Isentress at a rate similar to that observed in the patients receiving other HIV treatment that doesn’t contain Isentress.
U kliničkim su ispitivanjima zapaženi slučajevi raka, u sličnom postotku u bolesnika koji su primali Isentress kao i u bolesnika koji su primali druge terapije protiv HIV-a koje ne sadrže Isentress.
In clinical studies, cangrelor has been co-administered with bivalirudin, low molecular weight heparin, fondaparinux, and GP IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) with no apparent effect upon the pharmacokinetics or pharmacodynamics of cangrelor.
U kliničkim ispitivanjima kangrelor je istodobno primijenjen s bivalirudinom, heparinom male molekulske mase, fondaparinuksom i inhibitorima GP Iib/IIIa (abciksimab, eptifibatid, tirofiban) bez vidljivog učinka na farmakokinetiku ili farmakodinamiku kangrelora.
In clinical studies, CAPS patients who have uncontrolled over-production of IL-1 beta show a rapid response to therapy with canakinumab, i.e. laboratory parameters such as high C-reactive protein (CRP) and serum amyloid A (SAA), high neutrophil and platelet counts, and leukocytosis rapidly returned to normal.
U kliničkim ispitivanjima bolesnici s CAPS-om koji imaju nekontrolirano prekomjerno stvaranje IL-1 beta pokazuju brzi odgovor na terapiju kanakinumabom, tj. povratak na normalne vrijednosti laboratorijskih parametara poput C-reaktivnog proteina (CRP) i serumskog amiloida A (SAA), visokog broja neutrofila i trombocita te leukocitoze.
In clinical studies, cobicistat was co-administered with atazanavir or darunavir under fed conditions, in accordance with the Summary of Product Characteristics for these agents.
U kliničkim ispitivanjima, kobicistat je istovremeno primjenjivan s atazanavirom ili darunavirom na puni želudac u skladu sa Sažetkom opisa svojstava za te lijekove.
In clinical studies, colestilan had no effect on serum calcium levels over a period of up to one year.
U kliničkim ispitivanjima, kolestilan nije imao učinka na razine kalcija u serumu u razdoblju do godinu dana.
In clinical studies, dopaminergic adverse reactions, e.g. dyskinesia, were more common in patients who received entacapone and dopamine agonists (such as bromocriptine), selegiline or amantadine compared to those who received placebo with this combination.
U kliničkim su studijama neželjeni dopaminergički učinci, npr. diskinezija, bili češći u bolesnika koji su primali entakapon i agoniste dopamina (kao što je bromokriptin), selegilin ili amantadin, u usporedbi s onima koji su primali placebo s tom kombinacijom.
In clinical studies, dosing with 30 MU (300 micrograms)/day on 1 to 7 days per week was required to maintain the ANC > 2.0 x 109/l, with the median dose frequency being 3 days per week.
U kliničkim je ispitivanjima za održavanje ukupnog broja neutrofila na vrijednostima >2,0 x 109/l bila potrebna doza od 30 MU (300 mikrograma)/dan tijekom 1 do 7 dana na tjedan, s medijanom broja doza od 3 na tjedan.
In clinical studies, dosing with 30 MU/day (300 micrograms/day) on 1 - 7 days per week was required to maintain the ANC > 2.0 x 109/L, with the median dose frequency being 3 days per week.
U kliničkim je ispitivanjima bila potrebna primjena doze od 30 MU/dan (300 mikrograma/dan) 1 do 7 dana tjedno kako bi se održao ABN > 2,0 x 109/l, uz medijan učestalosti doziranja od 3 dana tjedno.
In clinical studies, dosing with 30 MU/day (300 μg/day) on 1 - 7 days per week was required to maintain the ANC > 2.0 x 109/l, with the median dose frequency being 3 days per week.
U kliničkim je ispitivanjima bilo potrebno primjenjivati dozu od 30 MU na dan (300 μg/dan) tijekom 1 - 7 dana tjedno da bi se apsolutni broj neutrofila održao na > 2,0 x 109/l, uz medijan učestalosti doziranja 3 dana tjedno.
In clinical studies, fatigue and headache were more common in patients treated with ledipasvir/sofosbuvir compared to placebo.
U kliničkim su ispitivanjima, umor i glavobolja bili su češćiu pacijenata liječenih ledipasvirom/sofosbuvirom nego placebom.
In clinical studies, haemorrhages were the most commonly reported reaction.
U kliničkim ispitivanjima krvarenja su bila najčešće prijavljivana reakcija.
In clinical studies, hypertension adverse events occurred in approximately 20% of subjects and approximately 6% of subjects had grade ≥ 3 hypertension events, but hypertensive crises occurred in < 0.5% of subjects.
U kliničkim ispitivanjima, hipertenzivni štetni događaji javili su se u otprilike 20% ispitanika i otprilike 6% ispitanika imalo je događaj hipertenzije 3. ili višeg stupnja, dok se hipertenzivna kriza javila u < 0,5% ispitanika.
In clinical studies, Ilaris has been safely administered with ULT.
U kliničkim ispitivanjima Ilaris se sigurno primjenjivao uz ULT.
In clinical studies, inadequate response to treatment was seen in 10–15% of the dogs.
U kliničkim ispitivanjima neadekvatni odgovor na liječenje uočen je u 10 - 15 % pasa.
In clinical studies, infections have been observed in patients receiving Cosentyx (see section 4.8).
U kliničkim ispitivanjima u bolesnika koji su primali Cosentyx bile su uočene infekcije (vidjeti dio 4.8).
In clinical studies, infusion-related reactions (IRR) and hypersensitivity reactions have been reported, with the majority being mild to moderate in severity (see section 4.8).
U kliničkim ispitivanjima prijavljene su reakcije povezane s infuzijom (RPI) i reakcije preosjetljivosti, koje su većinom bile blage do umjerene (vidjeti dio 4.8).
In clinical studies, LUMIGAN was used concomitantly with a number of different ophthalmic beta-blocking agents without evidence of interactions.
U kliničkim ispitivanjima LUMIGAN je primijenjen istovremeno s drugim oftalmološkim beta- blokatorima i nije bilo dokaza o interakcijama.
In clinical studies, luteal phase support was given according to study centres’ practice or according to the clinical protocol.
U kliničkim ispitivanjima podrška lutealnoj fazi davala se sukladno praksi pojedine klinike ili kliničkom protokolu.
In clinical studies, marked increases in plasma CPK to > 5x Upper Limit of Normal (ULN) without muscle symptoms occurred more commonly in Cubicin-treated patients (1.9%) than in those that received comparators (0.5%).
U kliničkim su ispitivanjima, izraženi porasti CPK u plazmi do >5x gornje granice normale bez mišićnih simptoma, bili češći u bolesnika liječenih Cubicinom (1,9%) nego u onih koji su primali lijekove usporedbe (0,5%).
In clinical studies, minimal accumulation was observed with either route of administration.
U kliničkim studijama minimalno nakupljanje zamijećeno je u oba puta primjene.
In clinical studies, neutralising antibodies have not been observed for Prolia.
U kliničkim ispitivanjima nisu otkrivena neutralizirajuća protutijela za lijek Prolia.
In clinical studies, neutralising antibodies have not been observed for XGEVA.
U kliničkim ispitivanjima nije zabilježeno stvaranje neutralizirajućih protutijela na lijek XGEVA.
In clinical studies, no dosage adjustment was required in elderly (> 65 years) patients exposed to pomalidomide.
U kliničkim ispitivanjima nije bila potrebna prilagodba doze u starijih (u dobi >65 godina) bolesnika izloženih pomalidomidu.
In clinical studies, no serious adverse reactions were attributed to the combination of afoxolaner and milbemycin oxime.
Tijekom kliničkih studija nisu zamijećene ozbiljnije nuspojave pridružene kombinaciji afoksolanera i milbemicin oksima.
In clinical studies, no serious adverse reactions were attributed to the combination of afoxolaner with milbemycin oxime.
Tijekom kliničkih studija nisu zamijećene ozbiljnije nuspojave pridružene kombinaciji afoksolanera s milbemicin oksimom.
In clinical studies, NO2 levels > 3 ppm or methaemoglobin levels > 7 % were treated by reducing the dose of, or discontinuing, INOmax.
U kliničkim ispitivanjima razine NO2 > 3 ppm ili methemoglobina > 7% liječene su smanjenjem doze ili prekidom davanja INOmax-a.
In clinical studies, oral doses of 10-30 mg/day of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
U kliničkim ispitivanjima, oralne doze aripiprazola od 10-30 mg na dan nisu imale značajnog učinka na metabolizam supstrata CYP2D6 (omjer dekstrometorfan/3-metoksimorfinan), CYP2C9 (varfarin), CYP2C19 (omeprazol) i CYP3A4 (dekstrometorfan).
In clinical studies, oral doses of 10-30 mg/day of aripiprazole had no significant effect on the metabolism of substrates of CYP2D6 (dextromethorphan/3-methoxymorphinan ratio), CYP2C9 (warfarin), CYP2C19 (omeprazole), and CYP3A4 (dextromethorphan).
U kliničkim ispitivanjima, peroralne doze aripiprazola od 10 do 30 mg/dan nisu imale značajnog učinka na metabolizam supstrata CYP2D6 (omjer dekstrometorfan/3-metoksimorfinan), CYP2C9 (varfarin), CYP2C19 (omeprazol) ni CYP3A4 (dekstrometorfan).
In clinical studies, over 1800 patients have been treated with LUMIGAN 0.3 mg/mL (multi-dose formulation).
U kliničkim ispitivanjima, s LUMIGAN 0,3 mg/ml višedoznim pripravkom liječeno je više od 1800 bolesnika.
In clinical studies, over 1800 patients have been treated with LUMIGAN 0.3 mg/ml.
U kliničkim ispitivanjima, s LUMIGAN 0,3 mg/ml kapima za oko liječeno je više od 1800 bolesnika.
In clinical studies, paradoxical bronchospasm was not observed with Brimica Genuair at its recommended dose.
U kliničkim ispitivanjima, nije primijećen paradoksalni bronhospazam s Brimica Genuairom u preporučenoj dozi.
In clinical studies, patients had a LVEF  50% at baseline.
U kliničkim ispitivanjima bolesnici su na početku ispitivanja imali LVEF ≥ 50%.
In clinical studies, patients received Lymphoseek up to 30 hours before surgery.
U kliničkim ispitivanjima, bolesnici primaju lijek Lymphoseek do 30 sati prije kirurškog zahvata.
In clinical studies, patients received prophylactic acetylsalicylic acid or alternative anti-thrombotic therapy.
U kliničkim ispitivanjima, bolesnici su primali profilaksu acetilsalicilnom kiselinom ili alternativnu antitrombotsku terapiju.
In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids and macrolides, no evidence of drug interactions with these medicines was identified.
U kliničkim ispitivanjima u bolesnika koji su primali TOBI Podhaler i nastavili uzimati alfa dornazu, bronhodilatatore, inhalacijske kortikosteroide i makrolide nisu pronađeni dokazi interakcija s tim lijekovima.
In clinical studies, patients with CrCl (creatinine clearance)  60 mL/min were included and treated at the recommended dose.
Bolesnici s CrCl (klirensom kreatinina)  60 mL/min bili su uključeni u klinička ispitivanja i liječeni preporučenom dozom.
In clinical studies, patients with creatinine clearance of  45 mL/min required no dose adjustments other than those recommended for all patients.
U kliničkim ispitivanjima u bolesnika s klirensom kreatinina  45 ml/min nisu bile potrebne druge prilagodbe doze osim onih preporučenih za sve bolesnike.
In clinical studies, patients with recent or ongoing clinically significant gastrointestinal disorder (e.g., severe vomiting and/or diarrhea) were excluded.
Iz kliničkih ispitivanja isključeni su bolesnici s nedavnim ili trenutačnim klinički značajnim gastrointestinalnim poremećajem (npr. teško povraćanje i/ili proljev).
In clinical studies, patients with severe renal impairment (creatinine clearance < 30 ml/min) or receiving dialysis were at greater risk of developing hypocalcaemia in the absence of calcium supplementation.
U slučaju izostanka nadopune kalcija, bolesnici s teškim oštećenjem funkcije bubrega (klirens kreatinina < 30 ml/min) ili bolesnici koji su na dijalizi u kliničkim su ispitivanjima imali povećan rizik za razvijanje hipokalcijemije.
In clinical studies, patients with uncontrolled or significant cardiac disease (e.g. recent myocardial infarction, congestive heart failure, unstable angina or clinically significant bradycardia) were excluded.
Bolesnici s nekontroliranim ili značajnim srčanim poremećajima (kao što je nedavni infarkt miokarda, kongestivno zatajenje srca, nestabilna angina ili klinički značajna bradikardija) bili su isključeni iz kliničkih ispitivanja.
In clinical studies, post-mortem examination of the injection sites performed in sows at most 50 days after the vaccination revealed limited lesions such as a discoloration and a granuloma in the majority of animals as well as necrosis or fibrosis (in approximately half of the animals).
U kliničkim ispitivanjima, post-mortem pregledi mjesta injiciranja provedeni na krmačama najviše 50 dana nakon cijepljenja pokazali su ograničene promjene poput promjene boje i granuloma kod većine životinja, kao i nekroze ili fibroze (kod približno polovine životinja).
In clinical studies, Prevenar 13 elicited an immune response to all thirteen serotypes included in the vaccine.
U kliničkim je ispitivanjima Prevenar 13 izazvao imunološki odgovor na svih trinaest serotipova uključenih u cjepivo.
In clinical studies, Rapiscan was administered to patients taking other cardioactive medicinal products (i.e., β-blockers, calcium channel blockers, ACE inhibitors, nitrates, cardiac glycosides, and angiotensin receptor blockers) without apparent effects on the safety or efficacy profile of Rapiscan.
U kliničkim ispitivanjima Rapiscan je primjenjivan u bolesnika koji su uzimali druge kardioaktivne lijekove (npr. β-blokatore, blokatore kalcijevih kanala, ACE-inhibitore, nitrate, kardijalne glikozide i blokatore angiotenzinskih receptora) bez očitih učinaka na sigurnosni i djelotvorni profil Rapiscana.
In clinical studies, rare cases of anaphylactic reactions have been observed in patients receiving Cosentyx.
U kliničkim ispitivanjima opaženi su rijetki slučajevi anafilaktičkih reakcija u bolesnika koji su primali Cosentyx.
In clinical studies, riociguat has shown to augment the hypotensive effects of PDE 5 inhibitors.
U kliničkim se ispitivanjima pokazalo da riocigvat pojačava hipotenzivni učinak inhibitora PDE5.
In clinical studies, serum transaminase elevations occurred during treatment and up to 4 months after the last dose of Zinbryta.
U kliničkim ispitivanjima povišenja razina serumskih transaminaza pojavila su se tijekom liječenja i do 4 mjeseca nakon zadnje doze Zinbryte.
In clinical studies, siltuximab was associated with an infusion related reaction or hypersensitivity reaction in 4.8% (severe reaction in 0.8%) of patients treated with siltuximab monotherapy.
U kliničkim ispitivanjima, siltuksimab je bio povezan s reakcijama povezanim s infuzijom ili reakcijama preosjetljivosti u 4,8% (teška reakcija u 0,8%) bolesnika liječenih siltuksimabom u monoterapiji.
In clinical studies, the 650 mg/m2 and 1,500 mg/m2 dose have both been used in patients in the age range 16 to 21 years.
U okviru kliničkih ispitivanja, u bolesnika dobi 16 do 21 godine primjenjivane su doze od 650 mg/m2 i 1500 mg/m2.
In clinical studies, the [90Y]-radiolabelled Zevalin after pretreatment with rituximab results in a significant radiation dose to the testes.
U kliničkim ispitivanjima Zevalina radioaktivno označenog izotopom [90Y] nakon početnog liječenja rituksimabom stvara značajne doze zračenja na testisima.
In clinical studies, the average olanzapine exposure was approximately 27 % higher in adolescents.
U kliničkim ispitivanjima prosječna izloženost olanzapinu bila je približno 27 % viša u adolescenata.
In clinical studies, the average olanzapine exposure was approximately 27% higher in adolescents.
U kliničkim ispitivanjima, prosječna izloženost olanzapinu bila je približno 27 % viša u adolescenata.